Riociguat for the treatment of pulmonary hypertension
- 9 March 2011
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 20 (4) , 567-576
Abstract
(2011). Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs: Vol. 20, No. 4, pp. 567-576.Keywords
This publication has 56 references indexed in Scilit:
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation‐induced degradationBritish Journal of Pharmacology, 2009
- Cellular and Molecular Basis of Pulmonary Arterial HypertensionJACC, 2009
- First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertensionEuropean Respiratory Journal, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- Molecular pathogenesis of pulmonary arterial hypertensionJournal of Clinical Investigation, 2008
- Inhaled Agonists of Soluble Guanylate Cyclase Induce Selective Pulmonary VasodilationAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vesselsJournal of Clinical Investigation, 2006
- High Frequency of BMPR2 Exonic Deletions/Duplications in Familial Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2006
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006